Ultragenyx Pharmaceutical(RARE)
Focus: Ultragenyx is a publicly-traded specialty pharmaceutical company focused on rare diseases, metabolic disorders, and gene therapy, with a market presence anchored by two approved biologics (DOJOLVI and MEPSEVII) and a robust pipeline spanning small molecules and AAV vectors.
Profile data last refreshed 3h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
29+1 this month
Stable — net +1 jobs in 30d
28 added, 27 removed. Backfill posture.
Should You Work at Ultragenyx Pharmaceutical?
AI assessmentBest for rare disease specialists and gene therapy researchers seeking high-impact work at a mission-driven company, but evaluate cash runway and execution risk carefully before committing to long-term tenure.
Why Work Here
- Mission-driven rare disease focus with 50 active pipeline programs spanning neurology, metabolic disease, and gene therapy — high impact per patient treated
Data completeness
7/9 — Strong
Company HealthStrong
Pipeline
Early-stage
50 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$434M
Key Products
Help build intelligence for Ultragenyx Pharmaceutical
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.